Alkem Reduces Prices of Denuril, Brand of Denosumab by 30% for the Treatment of Osteoporosis in Postmenopausal Women
Written By : Dr. Nandita Mohan
Written By : MD Brand Connect
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-01-16 06:30 GMT | Update On 2024-08-17 06:01 GMT
Advertisement
One of India's leading drug makers, Alkem Labs, has recently announced the reduction in the price of Denosumab injection sold under the brand name Denuril.
Denuril, which contains Denosumab, is approved by DCGI for the treatment of osteoporosis in postmenopausal women.
It is available as a single-dose prefilled syringe containing 60 mg per 1 ml solution for subcutaneous injection.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.